ATHERSYS, INC. (NASDAQ:ATHX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07.
|
Submission of Matters to a Vote of Security Holders. |
Athersys, Inc. (the Company) held its annual meeting of
stockholders (the Annual Meeting) on June7, 2017. Set forth below
are the voting results for each of the matters submitted to a
vote of the Companys stockholders at the Annual Meeting.
Proposal One Election of Directors.
All nominees for election to the Companys Board of Directors
named in the Companys proxy statement filed with the Securities
and Exchange Commission on April28, 2017 were elected, each to a
one-year term, with the following vote:
| SharesVotedFor | SharesWithheld | BrokerNon-Votes | ||||||||||
|
Gil Van Bokkelen |
36,550,799 | 1,428,451 | 52,329,759 | |||||||||
|
John J. Harrington |
36,121,223 | 1,858,027 | 52,329,759 | |||||||||
|
Lee E. Babiss |
35,427,273 | 2,551,977 | 52,329,759 | |||||||||
|
Jordan S. Davis |
34,058,926 | 3,920,324 | 52,329,759 | |||||||||
|
Ismail Kola |
36,269,117 | 1,710,133 | 52,329,759 | |||||||||
|
Lorin J. Randall |
36,311,330 | 1,667,920 | 52,329,759 | |||||||||
|
Jack L. Wyszomierski |
36,228,278 | 1,750,972 | 52,329,759 |
Proposal Two Ratification of the Appointment of the Companys
Independent Auditors.
The Companys stockholders ratified the appointment of Ernst Young
LLP as the Companys independent registered public accounting firm
for the fiscal year ending December31, 2017 with the following
vote:
|
For |
Against |
Abstain |
||
|
89,618,567 |
424,262 | 266,180 |
Proposal Three Approval of an Amendment to the Athersys, Inc.
Certificate of Incorporation (the Amendment) to increase the
number of authorized shares of common stock.
The Companys stockholders approved the Amendment with the
following vote:
|
For |
Against |
Abstain |
||
|
62,970,788 |
26,210,169 | 1,128,052 |
Proposal Four Advisory Vote on Named Executive Officer
Compensation.
The Companys stockholders approved, on an advisory basis, the
compensation of the Companys named executive officers with the
following vote:
|
For |
Against |
Abstain |
Broker Non-Votes |
|||
|
29,607,478 |
7,996,887 | 374,885 | 52,329,759 |
About ATHERSYS, INC. (NASDAQ:ATHX)
Athersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients. In the neurological area, the Company evaluated in a completed Phase II trial, the potential for MultiStem treatment of patients with a history of neurological damage from an ischemic stroke. The Company initiated a Phase II clinical study in the United States for the administration of MultiStem cell therapy to patients with a history of an acute myocardial infarction, or AMI.
